Ferring Pharmaceuticals will work with a Brazil-based organization to develop a new treatment for anal fissures and improve care for people with irritable bowel syndrome (IBS).
Ferring will collaborate with Instituto de Ciências Farmacêuticas (ICF) to make the treatment a reality, according to a Ferring press release. The treatment will use a mucoadhesive rectal delivery system to help patients with IBS who frequently suffer anal fissures.
"Ferring is committed to enhancing the quality of life and quality of care of IBD patients through innovative scientific research,” Alan Harris, Ferring's senior vice president, R&D Executive Office, said in the release. “This collaboration is focused on meeting a number of unmet needs – from alleviating the pain of anal fissures, to promoting faster healing, increasing patient adherence and developing more convenient dosing.”
Leonardo Teixeira, CEO of ICF, said the partnership will help address the unmet needs of doctors.
“We want to develop a ready-to-use and patient-compliant delivery system with mucoadhesive properties, to provide doctors with an alternative to current topical treatments and surgical options," Teixeira said in the release.
